A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster

M. Comba; S. Martorano-Raimundo; E. Venturino

Mathematical Modelling of Natural Phenomena (2012)

  • Volume: 7, Issue: 3, page 62-77
  • ISSN: 0973-5348

Abstract

top
A decision analytical model is presented and analysed to assess the effectiveness and cost-effectiveness of routine vaccination against varicella and herpes-zoster, or shingles. These diseases have as common aetiological agent the varicella-zoster virus (VZV). Zoster can more likely occur in aged people with declining cell-mediated immunity. The general concern is that universal varicella vaccination might lead to more cases of zoster: with more vaccinated children exposure of the general population to varicella infectives become smaller and thus a larger proportion of older people will have weaker immunity to VZV, leading to more cases of reactivation of zoster. Our compartment model shows that only two possible equilibria exist, one without varicella and the other one where varicella and zoster both thrive. Threshold quantities to distinguish these cases are derived. Cost estimates on a possible herd vaccination program are discussed indicating a possible tradeoff choice.

How to cite

top

Comba, M., Martorano-Raimundo, S., and Venturino, E.. "A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster." Mathematical Modelling of Natural Phenomena 7.3 (2012): 62-77. <http://eudml.org/doc/222352>.

@article{Comba2012,
abstract = {A decision analytical model is presented and analysed to assess the effectiveness and cost-effectiveness of routine vaccination against varicella and herpes-zoster, or shingles. These diseases have as common aetiological agent the varicella-zoster virus (VZV). Zoster can more likely occur in aged people with declining cell-mediated immunity. The general concern is that universal varicella vaccination might lead to more cases of zoster: with more vaccinated children exposure of the general population to varicella infectives become smaller and thus a larger proportion of older people will have weaker immunity to VZV, leading to more cases of reactivation of zoster. Our compartment model shows that only two possible equilibria exist, one without varicella and the other one where varicella and zoster both thrive. Threshold quantities to distinguish these cases are derived. Cost estimates on a possible herd vaccination program are discussed indicating a possible tradeoff choice.},
author = {Comba, M., Martorano-Raimundo, S., Venturino, E.},
journal = {Mathematical Modelling of Natural Phenomena},
keywords = {varicella zoster virus; vaccine; cost-effectiveness; epidemics},
language = {eng},
month = {6},
number = {3},
pages = {62-77},
publisher = {EDP Sciences},
title = {A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster},
url = {http://eudml.org/doc/222352},
volume = {7},
year = {2012},
}

TY - JOUR
AU - Comba, M.
AU - Martorano-Raimundo, S.
AU - Venturino, E.
TI - A Cost-Effectiveness-Assessing Model of Vaccination for Varicella and Zoster
JO - Mathematical Modelling of Natural Phenomena
DA - 2012/6//
PB - EDP Sciences
VL - 7
IS - 3
SP - 62
EP - 77
AB - A decision analytical model is presented and analysed to assess the effectiveness and cost-effectiveness of routine vaccination against varicella and herpes-zoster, or shingles. These diseases have as common aetiological agent the varicella-zoster virus (VZV). Zoster can more likely occur in aged people with declining cell-mediated immunity. The general concern is that universal varicella vaccination might lead to more cases of zoster: with more vaccinated children exposure of the general population to varicella infectives become smaller and thus a larger proportion of older people will have weaker immunity to VZV, leading to more cases of reactivation of zoster. Our compartment model shows that only two possible equilibria exist, one without varicella and the other one where varicella and zoster both thrive. Threshold quantities to distinguish these cases are derived. Cost estimates on a possible herd vaccination program are discussed indicating a possible tradeoff choice.
LA - eng
KW - varicella zoster virus; vaccine; cost-effectiveness; epidemics
UR - http://eudml.org/doc/222352
ER -

References

top
  1. A. M. Arvin, A. A. Gershon. Live attenuated varicella vaccine. Ann. Rev. Microbiol., 50 (1996), 59–100.  
  2. A. M. Arvin, A. A. Gershon. Live attenuated varicella vaccine. Ann Rev Microbiol., 50 (1996), 59–100.  
  3. M. Brisson, W. J. Edmunds, N. J. Gay, B. Law, G. De Serres. Modelling the Impact of Immunization on the Epidemiology of Varicella Zoster Virus. Epidemiology and Infection, 125 (2000), 651–669.  
  4. CDC. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 56 (2007), No. RR4, OpenURL.  
  5. Centers for Disease Control and Prevention. Prevention of varicella : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 45 (1997), No. RR-11, 35–40.  
  6. S. Deguen, A. Flahault. Impact on Immunization of Seasonal Cycle of Chickenpox. European Journal of Epidemiology, 16 (2000), 1177–1181.  
  7. O. Diekmann, J. A. P. Heesterbeek, J. A. J. Metz. On the definition and the computation of the basic reproduction ratio in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology, 28 (1990), No. 4, 365–382, Doi : .  Zbl0726.92018URI10.1007/BF00178324
  8. W. J. Edmunds, M. Brisson. The effect of vaccination on the epidemiology of varicella zoster virus. Journal of Infection, 44 (2002), 211–219.  
  9. J. E. Forde, B. Meeker. A model of varicella-zoster reactivation. Mathematical Biosciences and Engineering, 7 (2010), 765–777.  Zbl1259.92072
  10. G. P. Garnett, N. M. Ferguson. Predicting the effect of varicella vaccine on subsequent cases of zoster and varicella. Rev. Med. Virol., 6 (1996), 151–161.  
  11. G. P. Garnett, B. T. Grenfell. The Epidemiology of Varicella-Zoster Virus Infections : The Influence of Varicella on the Prevalence of Herpes Zoster. Epidemiology and Infection, 108 (1992), 513–528.  
  12. S. Hambleton, S. P. Steinberg, P. S. La Russa, E. D. Shapiro, A. A. Gershon. Risk of Herpes Zoster in adults immunized with varicella vaccine. J. Infect. Dis., 197 (2008), S196–199.  
  13. R. E. Hope-Simpson. The nature of herpes zoster : a long term study and a new hypothesis. Proc. Roy. Soc. Med., 58 (1965), 9–20.  
  14. J. Hornberger, K. Robertus. Cost-Effectiveness of a Vaccine To Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Ann Intern Med., 145 (2006), 317–325.  
  15. M. Karhunen, T. Leino, H. Salo, I. Davidkin, T. Kilpi, K. Auranen. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect., 138 (2010), No. 4, 469–481.  
  16. M. N. Oxman, M. J. Levin, G. R. Johnson, K. E. Schmader, S. E. Straus, L. D. Gelb, R. D. Arbeit, M. S. Simberkoff, A. A. Gershon, L. E. Davis, A. Weinberg, K. D. Boardman, H. M. Williams, J. Hongyuan Zhang, P. N. Peduzzi, C. E. Beisel, V. A. Morrison, J. C. Guatelli, P. A. Brooks, C. A. Kauffman, C. T. Pachucki, K. M. Neuzil, R. F. Betts, P. F. Wright, M. R. Griffin, P. Brunell, N. E. Soto, A. R. Marques, S. K. Keay, R. P. Goodman, D. J. Cotton, J. W. Gnann, Jr., J. Loutit, M. Holodniy, W. A. Keitel, G. E. Crawford, S.-S. Yeh, Z. Lobo, J. F. Toney, R. N. Greenberg, P. M. Keller, R. Harbecke, A. R. Hayward, M. R. Irwin, T. C. Kyriakides, C. Y. Chan, I. S. F. Chan, W. W. B. Wang, P. W. Annunziato, J. L. Silber. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med., 352 (2005), No. 22, 2271–2284.  
  17. M. N. Oxman, M.J. Levin. Vaccination against herpes zoster and postherpetic neuralgia. J Infect Dis., 197 (2008), Suppl. 2, S228–5236.  
  18. M. Socan, N. Berginc, J. Lajovic. Varicella susceptibility and transmission dynamics in Slovenia. BMC Public Health, 10 :360 (2010), 1–6.  
  19. M. C. Schuette, H. W. Hethcote. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol., 61 (1999), No. 6, 1031–1064.  Zbl1323.92211
  20. G. Soldato. Nuove strategie preventive vaccinali : vantaggi e limiti del vaccino antivaricella (New preventive vaccine strategies : advantages and limits of the vaccine against chickenpox). Thesis (Advisor Prof. C. Granchelli), University “G. D’Annunzio” of Chieti-Pescara, Italy, 2005.  
  21. N. Thiry, P. Beutels, F. Tancredi, L. Romanò, A. Zanetti, P. Bonanni, G. Gabutti, P. Van Damme. An economic evaluation of varicella vaccination in italian adolescents. Vaccine 22, (2004), 27-28, 3546–3562.  
  22. A. J. van Hoek, N. Gay, W. Opstelten, W. J. Edmunds. Estimating the cost-effectiveness of vaccination against Herpes Zoster in England and Wales. Vaccine, 27 (2009), No. 9, 1454–1467.  
  23. A. J. Van Hoek, A. Melegaro, E. W. Zaghenid, J. Edmunds, N. Gay. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine, 29 (2011), 2411–2420.  
  24. M. Wharton. The epidemiology of varicella-zoster virus infections. Infect Dis Clinics N Am, 10 (1996), 571–581.  

NotesEmbed ?

top

You must be logged in to post comments.

To embed these notes on your page include the following JavaScript code on your page where you want the notes to appear.

Only the controls for the widget will be shown in your chosen language. Notes will be shown in their authored language.

Tells the widget how many notes to show per page. You can cycle through additional notes using the next and previous controls.

    
                

Note: Best practice suggests putting the JavaScript code just before the closing </body> tag.